[144] Life360, Inc. SEC Filing
Rhea-AI Filing Summary
Life360, Inc. Form 144 notice reports a proposed sale of 10,000 common shares through The Charles Schwab Corporation with an aggregate market value of $845,800.00, scheduled approximately for 08/15/2025 on NASDAQ. The filing shows the shares were acquired as executive compensation on 10/10/2013. It also discloses three recent sales by John Coghlan in the past three months: 3,125 shares on 06/02/2025 (proceeds $190,605.11), 3,125 shares on 07/01/2025 ($205,934.79), and 3,125 shares on 08/01/2025 ($229,774.48). The filer affirms no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans to sell 10,000 shares; recent smaller sales recorded, no new material disclosures in this filing.
The Form 144 documents a scheduled sale under Rule 144 of 10,000 common shares via Charles Schwab with an indicated aggregate market value of $845,800.00 and an approximate sale date of 08/15/2025. The shares were acquired as executive compensation on 10/10/2013, and the filer certifies absence of undisclosed material adverse information. The filing also itemizes three small offloads by John Coghlan totaling 9,375 shares in the past three months with listed gross proceeds. From an investor-materiality standpoint, these disclosed transactions are routine insider sales and include required compliance representations.
TL;DR: Filing is a standard Rule 144 sale notice showing compliance and prior recent dispositions by the same individual.
The submission provides the required Form 144 information: broker name and address, number of shares to be sold, aggregate market value, acquisition date and nature (executive compensation), and recent sale history for the person for whose account the securities are to be sold. The document includes the statutory representation regarding material nonpublic information and a signature warning about false statements. No governance issues or undisclosed events are asserted in this filing; it serves primarily as regulatory disclosure of intended and recent sales.